[go: up one dir, main page]

WO2009020848A3 - RNAI-RELATED INHIBITION OF TNFα SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA - Google Patents

RNAI-RELATED INHIBITION OF TNFα SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA Download PDF

Info

Publication number
WO2009020848A3
WO2009020848A3 PCT/US2008/071886 US2008071886W WO2009020848A3 WO 2009020848 A3 WO2009020848 A3 WO 2009020848A3 US 2008071886 W US2008071886 W US 2008071886W WO 2009020848 A3 WO2009020848 A3 WO 2009020848A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnfα
silencing
glaucoma
rnai
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/071886
Other languages
French (fr)
Other versions
WO2009020848A8 (en
WO2009020848A2 (en
Inventor
Jon E. Chatterton
Abbot F. Clark
David P. Bingaman
Martin B. Wax
Adrian M. Timmers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Research LLC filed Critical Alcon Research LLC
Publication of WO2009020848A2 publication Critical patent/WO2009020848A2/en
Publication of WO2009020848A8 publication Critical patent/WO2009020848A8/en
Publication of WO2009020848A3 publication Critical patent/WO2009020848A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension.
PCT/US2008/071886 2007-08-03 2008-08-01 RNAI-RELATED INHIBITION OF TNFα SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA Ceased WO2009020848A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95380907P 2007-08-03 2007-08-03
US60/953,809 2007-08-03

Publications (3)

Publication Number Publication Date
WO2009020848A2 WO2009020848A2 (en) 2009-02-12
WO2009020848A8 WO2009020848A8 (en) 2009-07-23
WO2009020848A3 true WO2009020848A3 (en) 2009-09-03

Family

ID=40338355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/071886 Ceased WO2009020848A2 (en) 2007-08-03 2008-08-01 RNAI-RELATED INHIBITION OF TNFα SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA

Country Status (5)

Country Link
US (3) US20090035225A1 (en)
AR (1) AR067786A1 (en)
CL (1) CL2008002278A1 (en)
TW (1) TW200914052A (en)
WO (1) WO2009020848A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015168786A1 (en) * 2014-05-05 2015-11-12 Val-Chum, Limited Partnership Method for decreasing retinal ganglion cells degeneration
CN104498498A (en) * 2014-12-25 2015-04-08 广州市锐博生物科技有限公司 siRNA for inhibiting ADAM17 (a disintegrin and metalloprotease 17) genes and application of siRNA
WO2016103042A1 (en) * 2014-12-25 2016-06-30 Guangzhou Ribobio Co., Ltd. Compositions and methods for inhibiting expression of adamts-5 and adam17
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2018229653A1 (en) 2017-06-13 2018-12-20 Novartis Ag Intraocular lens compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058469A1 (en) * 2000-02-08 2001-08-16 Wax Martin B Methods for treating glaucoma
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
WO2007137129A2 (en) * 2006-05-19 2007-11-29 Alcon Research, Ltd. RNAI-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR α-RELATED CONDITIONS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531128B1 (en) * 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
EP2213738B1 (en) * 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058469A1 (en) * 2000-02-08 2001-08-16 Wax Martin B Methods for treating glaucoma
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
WO2007137129A2 (en) * 2006-05-19 2007-11-29 Alcon Research, Ltd. RNAI-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR α-RELATED CONDITIONS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TEZEL G ET AL: "TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 42, no. 8, July 2001 (2001-07-01), pages 1787 - 1794, XP002515257, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
WO2009020848A8 (en) 2009-07-23
TW200914052A (en) 2009-04-01
US20090035225A1 (en) 2009-02-05
AR067786A1 (en) 2009-10-21
US20150057336A1 (en) 2015-02-26
WO2009020848A2 (en) 2009-02-12
CL2008002278A1 (en) 2009-07-17
US8865670B2 (en) 2014-10-21
US20110135579A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
WO2007137129A3 (en) RNAI-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR α-RELATED CONDITIONS
WO2009020848A3 (en) RNAI-RELATED INHIBITION OF TNFα SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
MX2009001896A (en) Rnai-mediated inhibition of gremlin for treatment of iop-related conditions.
WO2006084217A3 (en) Rnai-mediated inhibition of ocular hypertension targets
WO2009020847A3 (en) Rnai-related inhibition of tnfa signaling pathway for treatment of ocular angiogenesis
NZ597947A (en) Klotho-beta for use in treating cancer, liver disorders, wasting syndrome and obesity-related diseases
MY139689A (en) Imidazotriazines as protein kinase inhibitors
WO2004089416A3 (en) Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
WO2008076949A3 (en) Quinazoline derivatives and methods of treatment
WO2008039397A3 (en) Method and intra-sclera implant for treatment of glaucoma and presbyopia
WO2008036361A3 (en) Reduced pressure treatment system having blockage clearing and dual-zone pressure protection capabilities
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
WO2000062790A3 (en) Soluble tumor necrosis factor receptor treatment of medical disorders
EP2006374A3 (en) Method for the purification and amplification of tumoral stem cells
WO2005117938A3 (en) Methods of treating ocular conditions
EP3156486A3 (en) Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
WO2008067382A3 (en) Rnai-mediated inhibition of aquaporin 4 for treatment of iop-related conditions
WO2005105829A3 (en) Caspase-2 inhibitors and their biological applications
Geng et al. Inhibition of titanium particle‐induced inflammatory osteolysis through inactivation of cannabinoid receptor 2 by AM630
WO2008121467A3 (en) Combination therapy for treating cancer
WO2005077462A3 (en) Cd70 inhibition for the treatment and prevention of inflammatory bowel disease
WO2005103254A8 (en) UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING
NZ596382A (en) Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases
WO2008019010A3 (en) Method of treating thermoregulatory disfunction with paroxetine
EP4342518A3 (en) Apparatus for controlling flow of urine in bladder or urethra

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08797024

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08797024

Country of ref document: EP

Kind code of ref document: A2